Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

Running, not enrolling · Phase 2

Conditions studied: Basal Cell Carcinoma

In brief

The purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) treated with Photodynamic Therapy (PDT) in order to develop new methods of treating BCC. Previous research suggests that PDT alters the immune response, possibly in a way that could promote better tumor clearance when combined with other treatments. Overall, participation in this study will help the study team better understand the anti-tumor immune response when BCC is treated with PDT.

Key facts

Study ID

NCT05020912

Run by

Case Comprehensive Cancer Center

People needed

18

Starts

2021-12-13

Expected to finish

2027-12-01

Last updated by the study team

2026-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be an adult parcticpant (> 18 yrs) who is scheduled to undergo BCC surgery (via Mohs surgery, ED\&C, or standard elliptical excision) within the Dermatologic Surgery unit of the Department of Dermatology, Cleveland Clinic.
• Must have at least one BCC tumor eligible for surgical removal
• Participants of any ethnic group are eligible for this trial.
• Must provide informed consent to participate in the trial.

You may not qualify if…

• Pregnant or breastfeeding
• Currently being treated for other cancers with medical or radiation therapy
• Known hypersensitivity to 5-aminolevulinic acid
• History of a photosensitivity disease, e.g., porphyria cutanea tarda

Where it is running

• Cleveland Clinic, Case Comprehensive Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.